Pancreatic Cancer Research

ResearcherLouisiana State UniversityActive in the last 2 years

Mohammad A. Al Efishat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2174-5007; OpenAlex author ID A5074457110. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. Do All Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy? Co-author DOI 10.3390/cancers18081195↗
  2. Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana. Co-author DOI 10.1002/jso.27901↗
  3. Stage III pancreatic cancer and the role of irreversible electroporation. Co-author DOI 10.1136/bmj.h521↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Lyons · 2 shared papers, 2025–2026 · strength 0.63
  2. Mei‐Chin Hsieh · 1 shared paper, 2026 · strength 0.39
  3. Quyen Chu · 1 shared paper, 2026 · strength 0.39
  4. Xiao‐Cheng Wu · 1 shared paper, 2025 · strength 0.25
  5. Hannah R. Malinosky · 1 shared paper, 2025 · strength 0.25
  6. Omeed Moaven · 1 shared paper, 2025 · strength 0.25
  7. Christopher Lee Wolfgang · 1 shared paper, 2015 · strength 0.08
  8. Matthew John Weiss · 1 shared paper, 2015 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.